Assessment of Clinical Complete Response After Chemoradiation for Rectal Cancer with Digital Rectal Examination, Endoscopy, and MRI: Selection for Organ-Saving Treatment by unknown
ORIGINAL ARTICLE – COLORECTAL CANCER
Assessment of Clinical Complete Response After Chemoradiation
for Rectal Cancer with Digital Rectal Examination, Endoscopy,
and MRI: Selection for Organ-Saving Treatment
Monique Maas, MD, PhD1, Doenja M. J. Lambregts, MD, PhD1, Patty J. Nelemans, MD, PhD2, Luc A. Heijnen,
MD1,3, Milou H. Martens, MD1,3, Jeroen W. A. Leijtens, MD4, Meindert Sosef, MD, PhD5, Karel W. E. Hulsewe´,
MD, PhD6, Christiaan Hoff, MD7, Stephanie O. Breukink, MD, PhD3, Laurents Stassen, MD, PhD3,
Regina G. H. Beets-Tan, MD, PhD1, and Geerard L. Beets, MD, PhD3
1Department of Radiology, Maastricht University Medical Centre, Maastricht, The Netherlands; 2Department of
Epidemiology, Maastricht University Medical Centre, Maastricht, The Netherlands; 3Department of Surgery, Maastricht
University Medical Centre, Maastricht, The Netherlands; 4Department of Surgery, Laurentius Hospital Roermond,
Roermond, The Netherlands; 5Department of Surgery, Atrium Medical Centre, Heerlen, The Netherlands; 6Department of
Surgery, Orbis Medical Centre, Sittard, The Netherlands; 7Department of Surgery, Leeuwarden Medical Centre,
Leeuwarden, The Netherlands
ABSTRACT
Background. The response to chemoradiotherapy (CRT)
for rectal cancer can be assessed by clinical examination,
consisting of digital rectal examination (DRE) and endo-
scopy, and by MRI. A high accuracy is required to select
complete response (CR) for organ-preserving treatment.
The aim of this study was to evaluate the value of clinical
examination (endoscopy with or without biopsy and DRE),
T2W-MRI, and diffusion-weighted MRI (DWI) for the
detection of CR after CRT.
Methods. This prospective cohort study in a university
hospital recruited 50 patients who underwent clinical
assessment (DRE, endoscopy with or without biopsy), T2W-
MRI, and DWI at 6–8 weeks after CRT. Confidence levels
were used to score the likelihood of CR. The reference
standard was histopathology or recurrence-free interval of
[12 months in cases of wait-and-see approaches. Diag-
nostic performance was calculated by area under the
receiver operator characteristics curve, with corresponding
sensitivities and specificities. Strategies were assessed and
compared by use of likelihood ratios.
Results. Seventeen (34 %) of 50 patients had a CR. Areas
under the curve were 0.88 (0.78–1.00) for clinical assess-
ment and 0.79 (0.66–0.92) for T2W-MRI and DWI.
Combining the modalities led to a posttest probability for
predicting a CR of 98 %. Conversely, when all modalities
indicated residual tumor, 15 % of patients still experienced
CR.
Conclusions. Clinical assessment after CRT is the single
most accurate modality for identification of CR after CRT.
Addition of MRI with DWI further improves the diagnostic
performance, and the combination can be recommended as
the optimal strategy for a safe and accurate selection of CR
after CRT.
In approximately 15–25 % of patients with rectal cancer
who are treated with chemoradiotherapy (CRT), no resid-
ual tumor is found in the resection specimen, indicating a
pathologic complete response (CR; ypT0N0).1 The
increasing interest in organ-saving treatment through local
excision or even a nonoperative treatment (a watch-and-
wait strategy) demands a reliable method to identify
patients with CR.2,3 Digital rectal examination (DRE) and
endoscopy have been the main assessment tools to evaluate
the response when the aim was to avoid surgery in specific
indications, such as after contact radiotherapy in small
rectal cancers.4 In the studies by Habr-Gama et al., who
 The Author(s) 2015. This article is published with open access
at Springerlink.com
First Received: 4 January 2015;
Published Online: 22 July 2015
M. Maas, MD, PhD
e-mail: moniquemaas@live.nl
G. L. Beets, MD, PhD
e-mail: g.beets@mumc.nl
Ann Surg Oncol (2015) 22:3873–3880
DOI 10.1245/s10434-015-4687-9
explored nonoperative treatment for CR in a wider group of
patients, DRE and endoscopy also served as main selection
tools.2,5 A drawback of endoscopy is that it only provides
information on the luminal side and not on the deeper
layers and the mesorectum. MRI can provide this addi-
tional information, which can be critical for decision
making.6 Although MRI has been widely adopted for the
primary staging of rectal cancer, restaging after CRT with
standard T2-weighted (T2W) MRI is hampered by the
difficulty of distinguishing fibrosis from viable tumor,
often leading to incorrectly classifying fibrosis as residual
tumor.6–8
Recently, diffusion-weighted MRI (DWI) has been
shown to provide more accuracy than T2W-MRI.9 Initially
in our center we relied on MRI as the first restaging method
and used endoscopy for further evaluation when MRI was
suggestive of a CR.3,10 With this selection strategy, a
substantial part of those with CR was missed. Therefore,
we changed the restaging strategy to routinely include DRE
and endoscopy in all patients.
The aim of this study was to evaluate the respective
value of clinical examination, consisting of DRE and




Fifty consecutive patients were prospectively included
within 3 years in a study on disease restaging after CRT.
Patients provided written informed consent for this
restaging study. CRT was indicated for a (1) very distal
tumor or (2) T4 tumor or (3) T3 tumor with involved
mesorectal fascia and/or N1 disease with distal or midrectal
location or (4) N2 status. CRT consisted of 28 fractions of
1.8 Gy radiation with capecitabine 825 mg/m2. Restaging
was scheduled 6–8 weeks after completion of CRT.
Clinical Assessment: DRE and Endoscopy
The patients were examined by one of three colorectal
surgeons (GB, SB, LS). At DRE, findings were classified
as: (1) normal bowel wall, (2) subtle residual abnormality
of the bowel wall, and (3) obvious residual tumor. All
patients underwent flexible endoscopy (Pentax Medical
Netherlands, Uithoorn, The Netherlands) of the rectum
after a rectal phosphate enema. Only white light imaging
was used with HDTV, and the images of the tumor area
were digitally stored. CR was defined as the absence of
residual tumor with only a flat, white scar with or without
teleangiectasia (Fig. 1). A small, flat ulcer with smooth
edges without signs of residual polypoid tissue was con-
sidered to be a potential CR (Fig. 1). Every other type of
ulcer or mass was considered as definite residual tumor
(Fig. 1). A biopsy was only performed in equivocal cases,
as judged by the surgeon during the endoscopy. Biopsy
results that indicated tumor or high-grade dysplasia were
considered proof of residual tumor. Absence of tumor or
high-grade dysplasia in biopsy samples was not considered
definite proof of CR because of the risk of sampling error.
For the purpose of this study, two experienced clinicians
(GB and MM, blinded to the MRI results and further
clinical outcome), in consensus, rated the combination of
the DRE and endoscopy findings and assigned a confidence
level score for the overall clinical assessment (Table 1).
MRI
All MRI examinations were performed at 1.5 T using a
phased array body coil [Intera (Achieva) or Ingenia, Philips
Medical Systems, Best, The Netherlands] and included
T2W-MRI in three orthogonal directions (axial, sagittal,
and coronal). Additional axial diffusion-weighted images
were obtained with b0 as the lowest and b1000 as the
highest b value. The sequence details are shown in Ap-
pendix. An intravenous bolus injection of 20 mg of
butylscopolamine (Buscopan; Boehringer Ingelheim,
Ingelheim, Germany) was administered to reduce peristaltic
movement; patients did not receive bowel preparation. An
apparent diffusion coefficient (ADC) map was automati-
cally calculated. The T2W-MRI and DWI axial images
were angled in identical planes. A reader with 5-year
specific experience in rectal cancer MRI (DL) scored the
T2W-MRI images together with the DWI (b1000 and ADC)
images for the presence of CR with confidence level scores
(Table 1). ycN0 was assessed on the basis of size and
morphology criteria.11 The reader had the pre-CRT MRI at
her disposal and was blinded to the endoscopy results and
histopathology (if available). Figure 1 shows examples of a
CR, equivocal score, and obvious residual tumor by T2W-
MRI. Figure 2 illustrates an example of DWI being decisive
in determining a CR when clinical assessment and T2W-
MRI show equivocal results.
Reference Standards
Histopathology of the total mesorectal excision (TME)
resection specimen was used as the reference standard,
with both high-grade dysplasia and carcinoma considered
as residual tumor. CR was defined as ypT0N0. Surgical
specimens were evaluated according to the method of
Quirke and Dixon.12 Some Patients underwent clinical
exams and endoscopy ? DWI-MRI in the first year of
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follow-up every 3 months and from the second year this
was performed every 6 months.3 For these patients, a local
recurrence-free follow-up time of C12 months was used as
a surrogate end point for a CR. For patients who underwent
a local excision of the remaining scar [transanal endoscopic
microsurgery (TEM)], the reference standard consisted of
histopathology of the specimen with C12 months’ follow-
up by MRI and endoscopy.
Statistical Analysis
Statistical analyses were performed with SPSS Statistics
20 (IBM, Armonk, NY) and Stata 11.0 (StataCorp, College
Station, TX). Receiver operator characteristics (ROC)
curves were constructed with confidence levels to assess
the diagnostic performance of clinical assessment and
MRI. The areas under the ROC curve (AUC) with
corresponding sensitivities and specificities were calcu-
lated for all modalities. The cutoff for sensitivity and
specificity was set between confidence level 2 and 3 at the
start of the study for both clinical assessment and MRI.
AUCs were compared between modalities by the method
of Hanley and McNeil.13 With logistic regression analyses,
predicted probabilities were calculated for the diagnostic
performance of the combination of MRI with clinical
assessment. With these predicted probabilities, a ROC
curve was constructed. The positive outcome measure was
the presence of a CR. In addition to the diagnostic per-
formance of the modalities, the positive and negative
likelihood ratios were calculated for the following: (1)
clinical assessment, (2) T2W-MRI with DWI, and (3) both
modalities combined.14 These likelihood ratios were used
to calculate posttest probabilities for a CR when the
modalities are combined by the multiplying pretest odds
FIG. 1 Response assessment with T2W-MRI (a–c) and with
endoscopy (d–f). Pre- and post-CRT MR images are shown. T
indicates tumor; arrows indicate scar or residual tumor after CRT.
a Typical CR at T2W-MRI, b equivocal image at T2W-MRI, and
c obvious residual tumor at T2W-MRI. d Typical endoluminal image
of CR with white scar with teleangiectasia. e Small ulcer with smooth
edges (arrows) but without residual polypoid tissue. Patients imaged
in (d) and (e) experienced sustained clinical CR at follow-up.
f Example of large ulcer that was deemed residual tumor after CRT
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Of the 50 included patients, 33 were men (66 %). The
median age was 67.5 years (range 34–88 years). Thirty-
four patients underwent a TME, and six underwent a TEM
as part of a study.
Seventeen patients experienced a CR (34 %): eight after
surgery (two after TEM, six after TME), and nine had a
clinical CR and were followed with a watch-and-wait pol-
icy, with a median follow-up of 17 months (range
12–20 months). One patient with residual tumor had
ypT0N1 disease. At primary staging, 72 % of patients had a
cT3 tumor (36 of 50), 20 % (10 of 50) had a cT2 tumor, and
8 % (4 of 50) had a cT4 tumor. At primary presentation, 38
(76 %) of 50 tumors were palpable at DRE. The median
interval between the last radiation dose and the restaging was
8 weeks (range 3–35 weeks), and between restaging MRI
and histopathology 9.5 days (range 0–74 days). The median
time between clinical assessment and restaging MRI was
0 days (range 0–56 days). At endoscopy, biopsies were
performed in 29 patients; findings were benign in 20 patients,
eight of which turned out to be false CRs after surgery. In
three patients the biopsy results revealed adenocarcinoma,
and high-grade dysplasia was found in six. In this small
sample, the sensitivity of a biopsy for persistent tumor was 9
(53 %) of 17, and the negative predictive value for persistent
tumor was 12 (60 %) of 20.
Diagnostic Performance
Figure 3 shows the ROC curves for MRI and clinical
assessment. Table 2 shows the diagnostic parameters for
the modalities. For clinical assessment, the AUC was 0.88
(95 % confidence interval 0.78–0.99), and sensitivity and
specificity were 53 and 97 %, respectively. For T2W-MRI
FIG. 2 Example of patient with a CR where T2W-MRI (a) revealed
marked hypointense residual wall thickening resulting with an
equivocal (confidence level 2) score. Clinical assessment (b) revealed
a white scar with some stenosis and distortion, and small superficial
ulceration, also resulting in an equivocal score. DWI (c) revealed
absence of diffusion restriction indicating CR
TABLE 1 Definitions of confidence level scores for assessment of complete response for every modality
CL Clinical assessment T2W-MRI findings DWI findings
CL
0
Positive biopsy result or gross residual
tumor at endoscopy with or without
palpable mass at DRE
Gross residual isointense mass and/or
involved nodes
Marked hyperintense signal at former tumor location
on b1000 images with low ADC
CL
1
Visible (with or without palpable) mass
or polypoid tissue with negative
biopsy
Small residual isointense mass and/or
involved nodes
Small but obvious area of hyperintense signal at former
tumor location on b1000 images with low ADC
CL
2
Ulcer with irregular borders and small
palpable ridge, ulcer or wall
thickening with negative biopsy
Irregular wall thickening with both
hypointense and isointense signal
Possible foci of hyperintense signal on b1000 images




Small nonpalpable ulcer with regular
borders and negative biopsy
Pronounced hypointense wall
thickening without isointense signal
and no involved nodes
No clear areas of residual hyperintense signal on b1000
images at former tumor location
CL
4
White scar with teleangiectasia, no
palpable lesions and negative biopsy
Normalized rectal wall or only subtle
wall hypointense wall thickening
and no involved nodes
No residual hyperintense signal on b1000 images or
low ADC at former tumor location
CL confidence level, T2W-MRI T2-weighted MRI, DWI diffusion-weighted imaging, DRE digital rectal examination, ADC apparent diffusion
coefficient
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and DWI, the AUC was 0.79 (95 % confidence interval
0.66–0.92), with a sensitivity of 35 % and a specificity of
94 %. The difference between clinical assessment and
T2W-MRI and DWI was not statistically significant
(P = 0.17).
Probability for CR with Combination of Methods
The positive likelihood ratio for a CR for clinical
assessment was 17.67 and for T2W-MRI and DWI 5.83.
The posttest probability (calculated with the positive like-
lihood ratios) for the presence of a CR for clinical
assessment was 90 % and for T2W-MRI and DWI MRI
was 75 %. When all three modalities were combined, the
posttest probability for a CR was 98 %, indicating that
when all three modalities predict a CR, this is correct in
98 % of the cases, with only a 2 % risk of missing residual
tumor. The negative likelihood ratio was 0.48 for clinical
assessment and 0.69 for T2W-MRI with DWI. These
likelihood ratios led to a posttest probability of a CR of
20 % for clinical assessment and 26 % for T2W-MRI and
DWI when either of the modalities indicates residual
tumor. When combining all modalities, this decreases to
15 %, meaning that when all three modalities indicate
residual tumor, there still is a 15 % chance for a CR.
Figures 4 and 5 show how the modalities complement
each other in assessment of response after CRT.
DISCUSSION
In this study, clinical assessment including DRE and
endoscopy proved to be the most accurate strategy to select
patients who may experience CR. The addition of MRI to
DWI, however, increases the identification CR rate to a
level that is reliable for clinical decision making. When
clinical assessment, T2W-MRI, and DWI all indicate a CR,
this is correct in 98 % of the cases, missing residual tumor
in only 2 %. When all modalities indicate residual tumor,
in 15 % of the cases, there is actually is a CR.
Rigid endoscopy and DRE have been the standard of
response assessment in the past treatment of rectal cancer
with radiotherapy alone.15 A continuing decrease in size
and disappearance of the tumor with healing of the mucosa

























FIG. 3 ROC curves for modalities. Clinical assessment consists of
endoscopy, DRE, and biopsy result (if available)
TABLE 2 Diagnostic parameters for clinical assessment, T2W-MRI and DWI, and all assessment modalities
Parameter Clinical assessment T2W-MRI and DWI All
Sensitivity 53 % 35 % 71 %
Specificity 97 % 94 % 97 %
PPV 90 % 75 % NA
NPV 80 % 74 % NA
AUC 0.88 (0.78–0.99) 0.79 (0.66–0.92) 0.89 (0.79–0.99)
LR positive 17.67 5.83 –
LR negative 0.48 0.69 –
Positive posttest probability 90 % 75 % 98 %
Negative posttest probability 20 % 26 % 15 %
Positive posttest probability is the probability of CR when both tests have positive results (indicate CR) and negative posttest probability is the
probability of CR when both tests have negative results (indicate residual tumor). Diagnostic parameters were calculated on the basis of
predefined cutoff in confidence levels between 2 and 3
T2W-MRI T2-weighted MRI, DWI diffusion-weighted MRI, NA not applicable, PPV positive predictive value, NPV negative predictive value,
AUC area under the receiver operator characteristic curve, LR likelihood ratio
CCR After Chemoradiation for Rectal Cancer 3877
series, rigid endoscopy was often replaced by flexible
sigmoidoscopy and imaging with endorectal ultrasound
with or without MRI was added.16 Habr-Gama et al.
showed that whitening of the mucosa (with or without
teleangiectasia) or a complete normalization of the tumor
bed should be considered a CR, a finding that is confirmed
in the current study.5 The literature has shown that residual
tumor can be found in any layer of the bowel wall,
regardless of tumor stage or presence of ulcer.17–20
Therefore, a major concern of clinical and endoscopic
assessment of response is the risk of missing such scattered
tumor deposits, leading to the cautious strategy to perform
a major resection whenever potential residual tumor is
suspected. This approach and the degree of subjectivity of
clinical assessment are illustrated in a study where DRE
only detected 3 of 14 patients with a CR, while a CR was
never falsely predicted in the 80 patients with residual
tumor.21 Given the fact that sampling errors occur regularly
in case of residual tumor, biopsies have only limited clin-
ical value for ruling out residual cancer.22 This variability
of tumor scatter could explain the 10–30 % early and late
regrowths in series of watchful waiting and underscores the
need for imaging methods that evaluate the deeper layers of
the bowel wall and the mesorectum.3,23–25
Endorectal ultrasound, FGD-PET-CT, and T2W-MRI all
have shown insufficient diagnostic performance to detect
residual tumor in fibrosis after CRT, and the strategy to err
on the safe side leads to overestimation of residual
tumor.9,26–28 The accuracy of T2W-MRI can be improved
by adding a DWI sequence, generating qualitative and
quantitative information on the cellular architecture on the
basis of differences in movement (diffusion) of water
FIG. 4 a Tumor (asterisks) before CRT. After CRT at T2W-MRI
(b), fibrosis (arrows) is found with absence of high signal on DWI (c),
suggestive of a CR. At endoscopy (d), a residual ulcer (arrows) is
found, indicating residual tumor. Patient refused surgery and has been
followed up for 3.5 years with stable MR image and a healed ulcer (e,
arrows), so is classified as having experienced CR
FIG. 5 a, b Distal tumor (asterisks) before CRT at T2W-MRI and
c DWI. After CRT at T2W-MRI (d) and DWI (e), residual tumor was
suspected (arrows). At endoscopy (f), CR (arrows) was determined,
and the patient was treated with wait-and-see policy. After 3 months,
DWI became normal; patient remained free of recurrent disease at
3.8 years of follow-up
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protons within the various tissues. Malignant tissues, with a
high cellular density, show restricted proton movement
leading to an increased signal. A meta-analysis on response
assessment in rectal cancer has shown that DWI improves
the diagnostic performance, mainly through increasing the
detection rate of response up to 84 %, along with a very
low risk of missing residual tumor.9 In the present study,
combined prediction of a CR on clinical assessment as well
as MRI including DWI resulted in a very high predictive
value for a CR of 98 %. With this strategy, however, about
one in three CRs is missed.
A clinically relevant question is whether it is necessary
to err so much on the safe side. A transanal excision of the
scar can provide histologic proof when there is an equiv-
ocal clinical and radiologic picture. The disadvantage is
that follow-up is somewhat more difficult, and in the event
of a recurrence, the ideal surgical plane may have been
violated. Another alternative is to extend the observation
interval for an additional 1–2 months, as it can take several
months before the full effect of the CRT becomes evi-
dent.29 The two approaches of local excision and extending
the observation interval will increase the number of
patients who can be offered organ preservation.
The most practical and cost-efficient strategy to identify
patients likely to experience clinical CR also depends on
local logistics and expertise. Currently, experience with
clinical assessment after CRT is limited and lacks stan-
dardization. Additionally, clinical assessment has a high
degree of observer variability. When restaging MRI is part
of the routine, it could serve as a first selection tool and
avoid unnecessary endoscopies in patients with obvious
residual tumor. When restaging MRI is not part of the
routine, DRE is by far the most cost-efficient way to
determine gross residual tumor. Regardless of the first
screening method, it is prudent in patients considered
candidates for organ preservation to use all methods: DRE,
endoscopy, and MRI. MRI provides information on the
presence of tumor in the deeper layers of the rectal wall,
the mesorectum, and the lymph nodes, and it provides
detailed images that can be used for serial follow-up.10
The most important limitation of the present study is the
relatively small sample size, and thus some caution in the
interpretation of the results is required. Second, the
prevalence of CR after CRT (34 %) is higher than gener-
ally reported in the literature (15–25 %) as a result of the
referral pattern to our center of patients with a good
response. Another limitation is that in some patients, the
reference standard was a lasting clinical CR at follow-up of
at least 1 year, with a median of 16.5 months. Although
most regrowths occur within the first year of follow-up, it
cannot be excluded that some will occur later. Addition-
ally, the range in interval between last radiation dose and
response evaluation and surgery is wide, which could have
an influence on our results.
In conclusion, clinical assessment with DRE and endo-
scopy is the most accurate strategy to identify patients
likely to experience CR, and it should be incorporated in a
post-CRT restaging strategy when organ preservation is
considered. Addition of MRI (including DWI) further
improves diagnostic performance, and the combination of
the two can be recommended as a strategy for a safe and
accurate selection of CR after CRT.
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APPENDIX
The standard rectal imaging protocol consisted of T2W
fast-spin echo sequences in three orthogonal planes (TR
8456–9558 ms, TE 130 ms, 25 echotrain length, 2–6 NSA,
0.78 9 1.14 9 3.00 mm voxel size, 30 slices, 4.37–
6.03 min acquisition time). Diffusion-weighted imaging
(TR/TE 4829/70 ms, EPI factor 53–61, 5 NSA,
1.8 9 2.3 9 5 mm acquisition voxel size, 24–50 slices,
5.33–10.37 min’ acquisition time) was performed with
DWIBS in half of the patients and with SPIR/SPAIR in the
remaining patients.
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